Serum sickness is a type III delayed hypersensitivity reaction which causes deposition of immune-complexes in the tissues. It has been reported with rituximab, and in this issue of the journal, there is a case report of a patient with relapsing remitting multiple sclerosis who developed a possible serum sickness after the third infusion of ocrelizumab. In this commentary, we discuss the current literature on serum sickness, and how to diagnose and manage it. We provide our opinion on this particular case, and encourage neurologists and patients to remain vigilant of such a possibility.

中文翻译：

---

ocrelizumab 输注后可能出现血清病的一例 ​​- 评论

血清病是一种 III 型迟发性超敏反应，会导致免疫复合物在组织中沉积。利妥昔单抗已有报道，在本期杂志中，有一例复发缓解型多发性硬化症患者在第三次输注 ocrelizumab 后可能出现血清病的病例报告。在这篇评论中，我们讨论了当前关于血清病的文献，以及如何诊断和管理它。我们就这个特殊案例提供我们的意见，并鼓励神经科医生和患者对这种可能性保持警惕。